Send us a text

In this week’s episode of On The Pen Live, guest Scott Liberto of PlanetScott.com joins to discuss his experience in the Survodutide clinical trial.

Survodutide is an investigational dual agonist targeting both the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim in collaboration with Zealand Pharma. This novel drug is designed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). 

ro.co/OTP

Support the show

Our Book Has Been Released!
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

MORE COMMUNITY!
📺 Watch Our Weekly Live Show: onthepen.tv
🆕 Discord: https://discord.gg/u4Ea8qqP

🤝 Visit Our Sponsor!
GLP-1 Ro Body Plan: https://www.ro.co/otp
Report The Shortage: https://www.ro.co/supply-tracker
Does your insurance cover GLPs? https://www.ro.com/checker

📲 Contact Me: [email protected]

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and...